siRNA for inflammatory diseases
- PMID: 19431074
siRNA for inflammatory diseases
Abstract
Infection is generally followed by inflammation; uncontrolled inflammation often precedes multiple organ failure and cancer. In this review, recent developments on the potential use of siRNAs in the treatment of inflammatory diseases of the liver, lung, joints and colon are summarized. Although target identification and a high degree of efficacy of siRNA have been achieved in cell culture studies in vitro, the major challenge has been the identification of acceptable delivery systems for in vivo application. In addition to delivery challenges, off-target effects and interferon response are major hurdles to overcome before a suitable siRNA formulation can be developed as a therapeutic. Nevertheless, recent preclinical and clinical studies have demonstrated promise in the treatment of diseases related to inflammation of the joints, lungs and colon, where delivery of siRNAs can be achieved without systemic administration.
Similar articles
-
siRNA delivery systems for cancer treatment.Adv Drug Deliv Rev. 2009 Aug 10;61(10):850-62. doi: 10.1016/j.addr.2009.04.018. Epub 2009 May 5. Adv Drug Deliv Rev. 2009. PMID: 19422869 Review.
-
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.Curr Opin Investig Drugs. 2008 Dec;9(12):1317-23. Curr Opin Investig Drugs. 2008. PMID: 19037838 Review.
-
Nanomedicinal delivery approaches for therapeutic siRNA.Int J Pharm. 2009 Sep 11;379(2):210-1. doi: 10.1016/j.ijpharm.2009.03.038. Epub 2009 Apr 5. Int J Pharm. 2009. PMID: 19716034 Review.
-
Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.Brief Funct Genomic Proteomic. 2007 Jun;6(2):112-9. doi: 10.1093/bfgp/elm015. Epub 2007 Jul 31. Brief Funct Genomic Proteomic. 2007. PMID: 17670766 Review.
-
Advances in synthetic siRNA delivery.Discov Med. 2010 May;9(48):418-30. Discov Med. 2010. PMID: 20515610 Review.
Cited by
-
Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes.Pharmacol Res. 2012 Jan;65(1):48-55. doi: 10.1016/j.phrs.2011.09.001. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21933712 Free PMC article.
-
Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition.PLoS One. 2012;7(11):e48567. doi: 10.1371/journal.pone.0048567. Epub 2012 Nov 12. PLoS One. 2012. PMID: 23152782 Free PMC article.
-
Alkane-modified short polyethyleneimine for siRNA delivery.J Control Release. 2012 Jun 10;160(2):172-6. doi: 10.1016/j.jconrel.2011.11.030. Epub 2011 Dec 2. J Control Release. 2012. PMID: 22155553 Free PMC article.
-
Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.Mol Ther. 2011 Dec;19(12):2163-8. doi: 10.1038/mt.2011.206. Epub 2011 Oct 4. Mol Ther. 2011. PMID: 21971426 Free PMC article.
-
Emergence of Small Interfering RNA-Based Gene Drugs for Various Diseases.ACS Omega. 2023 Jun 1;8(23):20234-20250. doi: 10.1021/acsomega.3c01703. eCollection 2023 Jun 13. ACS Omega. 2023. PMID: 37323391 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources